![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Industry Reports
Thermo Fisher Scientific Completes Acquisition of Finesse Solutions, Inc
Thermo Fisher Scientific Inc, the world leader in serving science completed its previously announced acquisition of Finesse Solutions, Inc., a leader in the development...
Production & Manufacturing
Mundipharma, Helsinn Expand Licensing and Distribution Agreements for Leading Anti-emetic Products
Mundipharma and Helsinn Group have expanded their collaboration, signing amendments to licensing and distribution agreements for anti-emetic prophylactic agents ALOXI® and AKYNZEO® to cover...
Production & Manufacturing
AMAG and Endoceutics Enter Into an Exclusive U.S. License Agreement for Intrarosa  (Prasterone)
AMAG Pharmaceuticals, Inc. and Endoceutics, Inc. announced that they have entered into an exclusive license agreement that provides AMAG with U.S. commercial rights to...
Clinical Trials
Delmar Pharmaceuticals announces dosing of first patient in Phase two clinical trial of VAL-083
DelMar Pharmaceuticals, Inc , a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Announced that patient dosing...
Clinical Trials
Aslan pharmaceuticals announces first patient enrolled in phase 1 study of Varlitinib in japan
ASLAN Pharmaceuticals , a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types announced that they are...
Industry Reports
Aurobindo Pharma buys four biosimilar drugs from TL Biopharmaceutical
Aurobindo Pharma Limited is pleased to announce the acquisition of four cell culture derived biosimilar products from TL Biopharmaceutical AG. As part of this...
Press Releases
Ovid Therapeutics and NeuroPointDX Announce Collaboration to Identify Biomarkers for Angelman Syndrome
Ovid Therapeutics, a privately held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, and NeuroPointDX, a...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read